X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Posaconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P-450 dependent enzyme lanosterol 14α-demethylase responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane.
Lead Product(s): Posaconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Noxafil-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2023
Details:
STENDRA (avanafil), an oral phosphodiesterase 5 (PDE5) inhibitor for treatment of erectile dysfunction, provides positive results from its OTC draft label comprehension study for its ED drug demonstrated understanding of the messages therein.
Lead Product(s): Avanafil
Therapeutic Area: Psychiatry/Psychology Product Name: Stendra
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Petros Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Endo obtained the rights to abaloparatide-subcutaneous injection and abaloparatide-transdermal patch, a novel formulation and route of administration currently undergoing clinical development. Endo, will be responsible for all commercial activities related to abaloparatide.
Lead Product(s): Abaloparatide Acetate
Therapeutic Area: Musculoskeletal Product Name: BA058
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Endo International
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 05, 2021
Details:
BioSpecifics received a royalty stream from Endo related to Endo's collagenase-based therapies, which currently include XIAFLEX, marketed by Endo Pharmaceuticals.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Urology Product Name: Xiaflex
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: BioSpecifics
Deal Size: $540.0 million Upfront Cash: $540.0 million
Deal Type: Acquisition December 02, 2020
Details:
The license agreement is initially focused on the development and commercialization of arfolitixorin as first-line treatment for metastatic colorectal cancer (mCRC) patients in Japan, which is projected to be the second largest addressable patient market for arfolitixorin.
Lead Product(s): Arfolitixorin,Oxaliplatin,Fluorouracil
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Isofol Medical
Deal Size: $100.0 million Upfront Cash: $103.0 million
Deal Type: Licensing Agreement November 02, 2020
Details:
Endo International plc presentation will include a general overview of collagenase clostridium histolyticum-aaes and will review data from the product's phase 3 pooled trial analyses.
Lead Product(s): Collagenase Clostridium Histolyticum
Therapeutic Area: Dermatology Product Name: Qwo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
